Compare RELL & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RELL | ADAG |
|---|---|---|
| Founded | 1947 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.1M | 222.2M |
| IPO Year | 2004 | 2020 |
| Metric | RELL | ADAG |
|---|---|---|
| Price | $19.92 | $2.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | ★ $25.50 | $9.91 |
| AVG Volume (30 Days) | ★ 342.9K | 323.0K |
| Earning Date | 10-07-2026 | 08-12-2026 |
| Dividend Yield | ★ 1.15% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $228,564,000.00 | N/A |
| Revenue This Year | $12.68 | N/A |
| Revenue Next Year | $9.21 | $129.59 |
| P/E Ratio | $230.96 | ★ N/A |
| Revenue Growth | ★ 9.41 | N/A |
| 52 Week Low | $9.37 | $1.30 |
| 52 Week High | $23.15 | $4.85 |
| Indicator | RELL | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 54.39 | 44.95 |
| Support Level | $15.83 | N/A |
| Resistance Level | $21.62 | $3.50 |
| Average True Range (ATR) | 1.15 | 0.23 |
| MACD | 0.08 | 0.06 |
| Stochastic Oscillator | 66.15 | 71.43 |
Richardson Electronics Ltd is a world-wide manufacturer of engineered solutions, green energy products, power grid and microwave tubes, and related consumables; power conversion and RF and microwave components including green energy solutions; tubes for diagnostic imaging equipment; and customized display solutions. It serve customers in alternative energy, healthcare, aviation, broadcast, communications, industrial, marine, medical, military, scientific, and semiconductor markets. Its products and services include design-in support, systems integration, prototype design and manufacturing, testing, logistics, etc. Its segments are Power and Microwave Technologies (PMT), Green Energy Solutions (GES), and Canvys. Majority of Sales is from PMT. Majority of sales is from North America.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.